Similar experiments were performed in models generated by implantation of KARPAS-299 ALCL cells and NB-1 neuroblastoma cells. In both the models, administration of CH5424802 led to tumor growth inhibition and tumor regression (Figure 2D). Tumor growth inhibition at 20 mg/kg was 119% for KARPAS-299 and 104% for NB-1 on day 20....CH5424802 showed a potent efficacy against ALK-addicted tumors, such as NSCLC expressing EML4-ALK, ALCL expressing NPM-ALK, and ALK-amplified neuroblastoma, in vitro and in vivo.